Navalign LLC Has $923,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Navalign LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,739 shares of the medical research company’s stock after selling 212 shares during the period. Navalign LLC’s holdings in Thermo Fisher Scientific were worth $923,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Austin Private Wealth LLC boosted its holdings in Thermo Fisher Scientific by 8.1% in the fourth quarter. Austin Private Wealth LLC now owns 654 shares of the medical research company’s stock worth $347,000 after purchasing an additional 49 shares in the last quarter. Values Added Financial LLC increased its holdings in shares of Thermo Fisher Scientific by 25.2% during the 4th quarter. Values Added Financial LLC now owns 958 shares of the medical research company’s stock valued at $508,000 after acquiring an additional 193 shares during the last quarter. Transform Wealth LLC lifted its holdings in Thermo Fisher Scientific by 0.9% in the 4th quarter. Transform Wealth LLC now owns 11,075 shares of the medical research company’s stock worth $5,882,000 after purchasing an additional 104 shares during the last quarter. Ritholtz Wealth Management boosted its position in Thermo Fisher Scientific by 7.0% during the fourth quarter. Ritholtz Wealth Management now owns 3,908 shares of the medical research company’s stock worth $2,074,000 after purchasing an additional 254 shares during the period. Finally, Trueblood Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $1,056,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $1.84 on Thursday, reaching $581.21. The stock had a trading volume of 1,034,640 shares, compared to its average volume of 1,617,943. The stock has a fifty day moving average price of $565.13 and a 200-day moving average price of $520.22. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a market capitalization of $221.62 billion, a P/E ratio of 37.63, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the firm earned $5.40 EPS. The company’s revenue was down 4.9% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. HSBC assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price on the stock. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. Robert W. Baird reissued an “outperform” rating and issued a $670.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $599.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.